Заблуди и факти за множествената склероза

Множествената склероза (МС) е прогресиращо заболяване. Въпреки че МС може да се прояви по различен начин при всеки човек, нейната основна биология е подобна при всички. Без значение с каква форма на МС е диагностициран даден пациент, прогресията на заболяването е налице от самото начало. Тук разглеждаме често обсъжданите заблуди и погрешни схващания за МС, хвърляйки светлина върху това какво всъщност означава прогресията на заболяването, как тя засяга хората с МС и как най-добре да я контролираме.

Референции:
1. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128(11):2705-2712.
2. Brownlee WJ, Altmann DR, Alves Da Mota P, et al. Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome. Mult Scler. 2017;23(5):665-674.
3. Cree BAC, Hollenbach JA, Bove R, et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol. 2019;85(5):653-666.
4. Kappos L, Butzkueven H, Wiendl H, et al. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Mult Scler. 2018;24(7):963-973.
5. Rashid W, Davies GR, Chard DT, et al. Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study. J Neurol Neurosurg Psychiatry. 2006;77(1):51-55.
6. Giovannoni G, Cutter G, Sormani MP, et al. Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Mult Scler Relat Disord. 2017;12:70-78.
7. Trojano M., et al. (2003) The transition from relapsing–remitting MS to irreversible disability: clinical evaluation. Neurol Sci, 24(Suppl. 5): S268–S270.
8. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9:observations on the progressive phase of the disease. Brain. 2006;129(3):584-594.
9. Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability accumulation in multiple sclerosis. Neurology. 2011;77(13):1246-1252.
10. Tutuncu M, Tang J, Zeid NA, et al. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler. 2013;19(2):188-198.
11. Giovannoni, G, et al. Brain Health: Time Matters in Multiple Sclerosis. Mult Scler Relat Disord. 2016 Sep;9 Suppl 1:S5-S48.
12. Dutta R, Trapp BD. Relapsing and progressive forms of multiple sclerosis: insights from pathology. Curr Opin Neurol. 2014;27(3):271-278.
13. Krieger SC, Sumowski J. New insights into multiple sclerosis clinical course from the topographical model and functional reserve. Neurol Clin. 2018;36(1):13-25.
14. Kavaliunas A, Manouchehrinia A, Stawiarz L, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler. 2017;23(9):1233-1240.

M-BG-00000444 
Материалът е одобрен до 05.2022 г.